Investigational drug · Phase 2
HU6
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver.
Phase 2Last checked: Nov 19, 2026Latest source record: May 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
11
Any phase or sponsor naming "HU6"
First trial start
2023
Sep 5, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HU6", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Alcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
- Fatty Liver
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HU6" as an intervention, largest first.
- Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic SteatohepatitisPivotal-lookingActive, not recruiting
Rivus Pharmaceuticals, Inc.Industry
NCT05979779 · 219 participants · Start Sep 5, 2023 · Primary completion Jan 21, 2025
Drug: HU6 · For: Non-Alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Fatty Liver
Sites: Chula Vista, California; Los Angeles, California; Montclair, California · 20 sites in all
- A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
Rivus Pharmaceuticals, Inc.Industry
NCT07491458 · 180 participants (planned) · Start Feb 13, 2026 · Primary completion Feb 2027
Drug: HU6 · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 31 sites in all
Rivus Pharmaceuticals, Inc.Industry
NCT04874233 · 80 participants · Start Apr 19, 2021 · Primary completion Nov 30, 2021
Drug: HU6; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Minneapolis, Minnesota
Rivus Pharmaceuticals, Inc.Industry
NCT05284617 · 67 participants · Start Oct 30, 2022 · Primary completion May 24, 2024
Drug: HU6; Placebo · For: Heart Failure With Preserved Ejection Fraction
Sites: Beverly Hills, California; Torrance, California; Hialeah, Florida · 15 sites in all
Rivus Pharmaceuticals, Inc.Industry
NCT04463017 · 64 participants · Start Aug 12, 2020 · Primary completion Mar 30, 2021
Drug: HU6 · For: NASH - Nonalcoholic Steatohepatitis
Sites: Saint Paul, Minnesota
Rivus Pharmaceuticals, Inc.Industry
NCT07170189 · 59 participants · Start Oct 13, 2025 · Primary completion Dec 4, 2025
Drug: HU6 · For: Overweight
Sites: Minneapolis, Minnesota
Rivus Pharmaceuticals, Inc.Industry
NCT06486558 · 43 participants · Start Jul 24, 2024 · Primary completion Nov 15, 2024
Drug: HU6 450 mg Tablet; HU6 150 mg Capsules x 3 (Total dose = 450 mg) · For: Healthy
Sites: Saint Paul, Minnesota
Rivus Pharmaceuticals, Inc.Industry
NCT04709913 · 30 participants · Start Jan 4, 2021 · Primary completion Apr 30, 2021
Drug: HU6 · For: NASH - Nonalcoholic Steatohepatitis
Sites: Minneapolis, Minnesota
- Safety and Pharmacokinetics of HU6Completed
Rivus Pharmaceuticals, Inc.Industry
NCT05433506 · 30 participants · Start Sep 15, 2022 · Primary completion Jan 30, 2023
Drug: HU6 Tablet; HU6 Capsule · For: Obese
Sites: Minneapolis, Minnesota
Rivus Pharmaceuticals, Inc.Industry
NCT06325930 · 8 participants · Start Mar 26, 2024 · Primary completion May 7, 2024
Drug: [14C]-HU6 · For: Healthy
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Immunomodulatory, antioxidant, and growth-promoting effects of Hylocereus undatus peel powder in Pacific white shrimp (Litopenaeusvannamei).
Mathew RT, Ashour M, Haroun M, et al. · Dev Comp Immunol 2026
- USP18 ameliorates atherosclerosis through inhibiting the activation of TAK1.
Li S, Li W, Long P, et al. · Int Immunopharmacol 2026
- Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review.
Wu Y, Song M, Chen X, et al. · Curr Heart Fail Rep 2025
- Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer's disease models.
Pallapati AR, Korkmaz F, Rojekar S, et al. · J Clin Invest 2025
- Exploring the role of the CD74+ cardiac macrophage subset in trastuzumab cardiotoxicity and its mechanisms.
Zhu M, Yang Y, Tang X, et al. · Biochim Biophys Acta Mol Basis Dis 2025
- Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial.
Pandey A, Lewis GD, Borlaug BA, et al. · JAMA Cardiol 2025
Also in development for Non-Alcoholic Fatty Liver Disease
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- GSK4532990Phase 23 trials
GSK · Non-alcoholic Fatty Liver Disease, Liver Diseases, Alcoholic, Nonalcoholic Fatty Liver Disease
- EfinopegdutideMK-6024, HM12525APhase 22 trials
Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
- MN-001Phase 21 trial
MediciNova · Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.